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One of the most extensively used transgenic mouse model of Alzheimer’s disease (AD) is APPswe/PS1dE9 mice, which over
express the Swedish mutation of APP together with PS1 deleted in exon 9. These mice show increase in parenchymal Aβ load
with Aβ plaques starting from the age of four months, glial activation, and deﬁcits in cognitive functions at the age of 6 months
demonstrated by radial arm water maze and 12-13 months seen with Morris Water Maze test. As gene transfer technology allows
the delivery of DNA into target cells to achieve the expression of a protective or therapeutic protein, and stem cell transplantation
may create an environment supporting neuronal functions and clearing Aβ plaques, these therapeutic approaches alone or in
combination represent potential therapeutic strategies that need to be tested in relevant animal models before testing in clinics.
HerewereviewthecurrentutilizationofAPPswe/PS1dE9miceintestinggenetransferandcelltransplantationaimedatimproving
the protection of the neurons against Aβ toxicity and also reducing the brain levels of Aβ. Both gene therapy and cell based therapy
may be feasible therapeutic approaches for human AD.
1.Introduction
Recent advances in the ﬁeld of gene transfer technology
have allowed the delivery of DNA into target cells of the
recipient based on the use of viral systems for gene therapy.
This technology allows the delivery of DNA to target cells to
achieve the expression of a protective or therapeutic protein
and also in neurodegenerative diseases, including Alzheim-
er’s disease (AD). On the other hand, the cell therapy-based
applications in combating AD are based on the rationale of
replacement of functionally lost neurons by transplantation
of neuronal stem or progenitor cells, improvement in di-
minished neuronal function by creating an environment
aiding at neuronal recovery, or clearing of toxic beta-amyloid
(Aβ) plaques by phagocytic cells. Since AD is a multifactorial
disorder that progresses slowly, it is important to choose
a gene transfer approach that allows lengthy expression of
the therapeutic gene and/or a cell-based therapeutic strategy
that results in suﬃcient and preferably long-term reduction
in Aβ levels. The central nervous system (CNS) is a unique
site that poses challenges to the delivery of therapeutics as
eﬃcient delivery requires the crossing of the blood brain
barrier (BBB). The targets of gene therapy for AD fall into
four main categories: catabolism of amyloid precursor pro-
tein(APP)andremovalofAβ,neuroprotectivegenes,growth
factors, and apolipoprotein E (ApoE) alleles. The main
strategies adopted for viral vector-mediated gene delivery to
the CNS include direct delivery into the brain parenchyma
and peripheral delivery. Similarly, although the brain is an
evident target tissue of the cell-based therapy, cells admin-
istered peripherally may function also in peripheral sites.
APPswe/PS1dE9 mice accumulate toxic Aβ in the brain
parenchyma, and also around the blood vessels as cere-
bral amyloid angiopathy (CAA) upon aging, making them2 International Journal of Alzheimer’s Disease
excellent models for AD’s amyloidosis. Importantly, similar
to some clinical AD cases, the behavioral deﬁcits correlate
with the soluble Aβ levels in the brain of this mouse line.
Therefore, these mice oﬀe rav a l u a b l et o o li ns t u d i e so f
cellmediatedAβ clearance.StudiesutilizingAPPswe/PS1dE9
mice as a model of AD are discussed below in the context of
virus vector-mediated and cell-based experimental therapy
in vivo.
2.APPswe/PS1dE9Mice asa Model of AD
AD is a multifactorial disorder leading to progressive memo-
ry loss and eventually death. One of the pathological features
of the disease is the abnormal accumulation of toxic Aβ
peptides in the brain parenchyma [1, 2]. These peptides are
cleavage products derived from the amyloid precursor pro-
tein (APP) through endoproteolytic cleavage operated by
speciﬁc secretases, BACE-1 and γ-secretase [1, 2]. APP mu-
tations alter the processing of the protein by shifting the
nonamyloidogenic processing towards amyloidogenic pro-
cessing which eventually leads to generation of highly ﬁbril-
logenic, toxic Aβ1-42 peptides [1, 2]. Presenilin-1 (PS-1)
and presenilin-2 (PS-2) function as a catalytic site for γ-
secretase and mutations in PS-1 or PS-2 further increase the
production of amyloidogenic Aβ [1, 2]. Human AD neurons
also contain intraneuronal inclusions of hyperphosphory-
lated tau protein, called neuroﬁbrillary tangles (reviewed by
[3, 4]). These abnormal protein inclusions alter neuronal
f u n c t i o na n dr e s u l ti nn e u r o nd e a t h .M u t a t i o n si nA P Pa n d
PS1 have been linked to familial, inherited forms of AD,
which account less than 10 % of the clinical AD cases (re-
viewed by [5, 6]). Indeed, the majority of the diagnosed AD
patients have a sporadic form of the disease in which the
underlying cause remains unknown. Mutations in tau have
not been linked to clinical AD but are the underlying cause
ofanotherneurodegenerativedisordercalledfrontotemporal
dementia [3, 4].
AD has been widely studied exploiting various in vitro
models and with the development of molecular biology
methods, transgenic mouse models have become increas-
ingly popular. Up to date, a wide range of transgenic mouse
models based on APP expression have been generated (re-
viewed by [7, 8]). Despite their utmost importance in the
ﬁeld of AD research, none of the models developed so far
are able to recapitulate the full neuropathological features of
clinical human AD. In general, APP transgenic mice develop
Aβ plaques and memory deﬁcits but lack frank neuron loss
and neuroﬁbrillary tangles [7, 8]. Moreover, not all APP
transgenics develop memory deﬁcits independent of Aβ ag-
gregation and not all plaque bearing mice develop memory
deﬁcits. Overexpression of the PS1 gene alone does not result
inplaques,buttogetherwithAPP,ithastensthedevelopment
of plaques; tau overexpression leads to memory deﬁcits and
tangle formation but does not result in plaques [7, 8].
Overexpression of all these genes within one mouse line—
named the triple transgenic mice—recapitulate memory
deﬁcits, plaques, and tangles.
To date, there is no feasible model for the sporadic form
of AD. Some larger animals such as monkeys [9], old dogs
[10, 11] and cats [12] develop spontaneous Aβ plaques.
AD pathology often coexists with infarcts, α-synuclein, and
aggregates of TAR DNA-binding protein-43 (TDP-43) [13,
14]. Thus, any model for AD is a compromise and should
be chosen to answer the speciﬁc question addressed by the
study. Nonetheless, with the exception of the time of onset
of the disease, pathological features of both sporadic and
familial human AD are similar [15].
APPswe/PS1dE9 mice, described by Jankowsky et al. in
2004, overexpress the Swedish mutation of APP, together
with PS1 deleted in exon 9 [16]. Overexpression of the trans-
geneconstructleadstooverproductionofAPPandPS1splice
variants with concomitant increase in parenchymal Aβ load.
These mice develop the ﬁrst Aβ plaques at 4 months of age.
Activated microglia and astrocytes surround the ever grow-
ing deposits. By 12 months of age, the mice develop deﬁcits
in a widely used behavioral test measuring spatial navigation
and reference learning, Morris water maze (MWM), but
memory deﬁcits can be seen in radial arm water maze even
at 6 months of age [17]. Even though these mice do not
exhibitfrankneuronalloss,theAPPswe/PS1dE9micedisplay
a variety of other clinically relevant AD-like symptoms.
These include mild neuritic abnormalities [18], local plaque-
r e l a t e dl o s si nn e u r o n a la c t i v i t y[ 19], increased mortality,
high prevalence to unprovoked seizures [20], and age-
dependent deﬁcits in the pre- and postsynaptic cholinergic
transmission [21] and similar to some clinical AD cases,
the soluble Aβ levels correlate with behavioral deﬁcits in
these mice at 12 months of age [22]. Due to the fact that
the mice develop parenchymal Aβ pathology and memory
deﬁcitsevidencedalreadyby6monthsofage[17],thesemice
oﬀer a valuable tool in studies aiming at the development of
new therapeutic approaches targeted speciﬁcally against the
plaques and related neuroinﬂammation.
3. GeneTransfer-Based Therapy Applications
Recent advances in the ﬁeld of gene transfer technology have
allowed the delivery of DNA into target cells of the recipient
based on the use of viral systems for gene therapy. This tech-
nology allows the delivery of DNA to target cells to achieve
the expression of a protective or therapeutic protein. Viral
vectors are a powerful tool that allows transgene delivery
to speciﬁc locations in vivo, yet numerous aspects must be
considered in order to achieve eﬃcient gene delivery. These
include choice of viral vector, mode and location of delivery,
duration and location of transgene expression, and potential
toxicity associated with the approach. Delivery issues and
immune responses to viral vectors remain the major limita-
tions of CNS gene transfer (reviewed in [23, 24]).
The CNS is a unique site that poses challenges to the
de livery of therapeutics as eﬃcient delivery requires the
crossing of the BBB. While there are a large number of tech-
niques to transfer genes in vivo, the main strategies adopted
for viral vector-mediated gene delivery to the CNS include
direct delivery into the brain parenchyma and peripheral
delivery. Direct delivery into the brain allows targeted
expression of the gene of interest in a relatively limited area.
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safe as the immune response is minimal when the vector is
injected directly into the CNS. Moreover, transduction can
be performed unilaterally, thus allowing an opportunity to
compare alterations in the contralateral side of the same
animal. Peripheral delivery relies on the ability of viral vec-
tors to undergo transport to other regions of the CNS. Viral
vectors can be targeted to multiple regions via minimally
invasive administration, including intravenous administra-
tion and intramuscular injections.
Several diseases of the CNS require long-term treatment.
Since AD is a multifactorial disorder that progresses slowly,
it is important to choose an approach that allows lengthy
expression of the therapeutic gene. Lentivirus (LV), aden-
ovirus (AV), adeno-associated virus (AAV) and baculovirus-
(BV-) derived gene transfer vehicles have been produced,
each with advantages and potential drawbacks. LV vectors
are emerging as one of the preferred gene delivery candidates
for CNS because of their ability to transfer a relatively large
transgene into nondividing neuronal cells. While LV inte-
gration into the host genome allows long-term transgene
expression, there is a low risk of insertional mutagenesis (re-
viewed in [25] ) .A Vv e c t o r sc a na l s oi n f e c tm o s tc e l lt y p e s ,
including neurons and can be manipulated to accommodate
relatively large DNA inserts. However, they have potential
for therapies of limited duration, as permanent expression
of the transgene is not achieved. While AAV vectors are in
many ways comparable to LV vectors, their major drawback
isthattheircloningcapacityisrelativelysmall,precludingthe
transferofgenesoverﬁvekilobasesinsize(reviewedin[26]).
BV represents still another interesting viral vector with some
advantages as a gene therapy vector [27]. BVs can be easily
and quickly produced in high titers, and they can transduce
bothdividingandG1/S-arrestedcells.Theyarealsorelatively
safe, because insect host-derived viruses do not replicate in
vertebrate cells. However, because the virus is produced in
insect cells, which results in the display of foreign glycopro-
teins, the risk of immunogenic responses and inactivation by
the blood complement system by classical pathway is high
[27]. However, as the brain is an immune privileged tissue,
the risks of immunogenic responses remain quite minimal.
BVs seem to be especially useful for the targeting of choroid
plexus cells.
The targets of gene therapy for AD fall into four main
categories: catabolism of APP and removal of Aβ,n e u r o p r o -
tective genes, growth factors, and ApoE4 alleles (reviewed
in [28]). Studies utilizing APPswe/PS1dE9 mice as a model
of AD are discussed below in the context of virus vector-
mediated experimental in vivo gene therapy.
4.TherapeuticApproachesTargetedtoVirus
Vector-Mediated Removal of Aβ
Depletion of Aβ in aﬀectedareas of the brain can be achieved
by using viral vectors to deliver small interfering RNAs
for enzymes involved in APP catabolism, antibodies that
reduce the amount of existing Aβ, and enzymes that degrade
Aβ. Animal models of AD have been utilized to test the
therapeutic and disease-modifying abilities of each of these
approaches in vivo. The studies reviewed below have utilized
the APPswe/PS1dE9 mouse model to experimentally assess
the potential of virus vector-mediated gene delivery targeted
to Aβ removal.
Delivery of Aβ antibodies is known to reduce Aβ burden
in mice modelling AD. In 2009, Wang et al. delivered an
anti-Aβ single-chain antibody (scFv) intrahippocampally,
intraventracularlyorintramuscularlyinto9-montholdAPP-
swe/PS1dE9mice[29].Thetransgenewasrobustlyexpressed
for up to three months when an AAV vector was utilized
as the gene transfer vehicle. Immunohistochemical analyses
showed that the Aβ burden was reduced by approximately
30% in the hippocampi of scFv injected mice. Interest-
ingly, ELISA analyses showed that both intramuscular and
intracranial delivery of the gene also clearly reduce Aβ
burden. This suggests that targeting the brain metabolites
relevant for the disease pathology and leaking out of the
brain by peripheral administration of a viral vector is a good
alternative to the more invasive intracranial administration.
In the brain, transgene expression colocalized with neuronal,
but not glial markers, suggesting that the transgene was
mainly expressed in neurons. Importantly, gene transfer
did not elicit an inﬂammatory reaction. More recently, the
same group reported that intramuscular delivery of the same
vector into 3-month-old APPswe/PS1dE9 mice attenuated
Aβ accumulation and cognitive impairment when analyzed
6 months later [30]. Intramuscular delivery of the vector
resulted in transgene expression at the site of injection, in
the liver, and in the olfactory bulb without concomitant in-
ﬂammation. Peripheral administration of a viral vector car-
rying scFv is a potentially safe and less invasive alternative to
intracranial gene transfer.
Neprilysin is a major enzyme capable of degrading Aβ in
the brain [31, 32]. Reduction of neprilysin occurs in early
stages of AD and it is downregulation contributes to Aβ
accumulation in the brain [33–37]. To assess the therapeutic
potential of neprilysin gene replacement, El-Amouri et al.
used an LV vector as a gene delivery system to over-express
human neprilysin in 3-month-old APPswe/PS1dE9 mice
[38]. The vector was injected into the cortical/hippocampal
area and the mice were assessed four months after gene de-
livery. Using this approach, neprilysin was overexpressed
threefold, and the majority of the expression occurred in
neurons. The overexpression of neprilysin reduced cognitive
impairment and correlated with a reduction in amyloid bur-
den and attenuation of oxidative stress and glial activation.
These ﬁndings are in line with beneﬁcial eﬀects of virus
vector-mediated neprilysin over-expression studies reported




Vast evidence exists for the role of oxidative stress in the
pathogenesis of AD (reviewed in [44, 45]). An endogenous
defense system is activated during oxidative stress that aims
to alleviate the harm caused by reactive oxygen species.4 International Journal of Alzheimer’s Disease
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a tran-
scription factor that is activated during oxidative stress to
induce defensive gene expression that promotes cell survival
(reviewed in [46, 47]). The Nrf2 pathway is attenuated in
human AD brain [48] and concomitantly with increased Aβ
depositionintheAPPswe/PS1dE9andotherAPP/PS1mouse
models [49, 50]. To exploit the Nrf2 pathway therapeutically,
we recently overexpressed human Nrf2 in the hippocampi
of APPswe/PS1dE9 mice using an LV vector [51]. At the
time of gene therapy, the mice were nine months of age and
exhibiting full-blown AD pathology. Assessment of the mice
six months after gene transfer revealed robust and sustained
gene expression especially in neurons without associated
toxicity. Modulation of Nrf2 levels in the brain attenuated
memory impairment and reduced astroglial activation, sug-
gesting that LV-mediated gene transfer of an endogenous
protectivegeneisbeneﬁcialagainstoxidativestressassociated
with AD.
6.APPswe/PS1dE9Mice inthe Development of
Cell Therapy
The cell therapy-based applications in combating AD are
based on the rationale of replacement of functionally lost
neurons by (i) transplantation of neuronal stem or progeni-
tor cells, (ii) improvement in diminished neuronal function
by creation of an environment aiding at neuronal recovery,
or (iii) clearing of preexisting toxic Aβ plaques by phagocytic
cells.
Even though loss of cholinergic neurons is an evident
part of AD pathology, APPswe/PS1dE9 mice, similar to most
other AD transgenic mouse models, do not exhibit frank
neuronal loss [16, 18]. In fact, only the triple transgenic
m i c es h o ws o m ed e g r e eo fn e u r o n a ll o s s[ 52]. The APP-
swe/PS1dE9 mice have recently been shown to have reduced
release of acetylcholine and decreased potency of carbachol-
induced G-protein activation in cortical membranes, indi-
cating that mild deﬁcits do occur in the cholinergic system
without clear neuronal loss [18, 53]. On the other hand,
APPswe/PS1dE9 mice accumulate toxic Aβ in the brain
parenchyma,andalsoaroundthebloodvessels,asCAAupon
aging, making them excellent models for Alzheimer’s amy-
loidosis [54]. Importantly, similar to some clinical AD cases,
the behavioral deﬁcits correlate with the soluble Aβ levels in
the mouse brain [55]. Therefore, these mice oﬀer a valuable
tool in studies of cell-mediated Aβ clearance. Indeed, all
cell-based therapy applications developed using the APP-
swe/PS1dE9miceaimprimarilytoremovetoxicAβ peptides.
Cell transplantation studies using other than phagocytic cell
types, such as neuronal progenitor cells, have utilized differ-
ent transgenic mouse models (APP23 mice, [56]).
7. Bone MarrowStem Cell-Based
Therapy Approaches
APPswe/PS1dE9 mice were utilized to discover the initial
role and contribution of peripheral phagocytic cells in Aβ
clearance. One of the primary ﬁndings was the contribution
of the hematopoietic system to the inﬂammatory reactions
in the AD-like mouse brain. By using novel, bone marrow
(BM) chimeric mice (described by [57]), BM-derived mono-
cytic cells were shown to inﬁltrate into the brains of the
APPswe/PS1dE9 transgenic mice [58]. These cells clearly
associated with Aβ deposits, suggesting that aggregated Aβ
peptides attracted them. When the brains of the APP-
swe/PS1dE9 mice were challenged with additional inﬂam-
matory stimuli, lipopolysaccharide (LPS), inﬁltration of the
peripheral cells was dramatically increased. LPS also in-
creasedtheassociationoftheperipheralmonocyticcellswith
theAβdepositsandcausedconcurrentreductioninthebrain
Aβ burden. This suggests that the peripheral monocytic cells
were actively taking part in the clearance of Aβ [58, 59].
The capacity of the cells to clear Aβ was further proven with
anexvivoassay,in whichBMmonocytic cellswerecultivated
on top of aged APPswe/PS1dE9 mouse brain sections. These
brain sections contained Aβ in its natural conformation
resembling the in vivo situation in the AD mouse brain.
Indeed,monocyticcellseﬃcientlyclearedAβexvivo[60,61].
Moreover, when the cells were transplanted intrahippocam-
pally into the brains of the APPswe/PS1dE9 mice, the cells
also cleared Aβ in vivo (Magga et al., [61]), further estab-
lishing the foundation for justiﬁcation into development of
BM cell-based therapy for AD.
APPswe/PS1dE9 transgenic mice have also been used in
otherstudiesassessingthesigniﬁcanceofperipheralimmune
cells in the clearance of Aβ. Keene and coworkers trans-
planted lethally irradiated APPswe/PS1dE9 mice with BM
cells deﬁcient in prostaglandin E2 receptor subtype 2 (EP2)
[60]. EP2 is a receptor mediating microglial proinﬂamma-
tory reactions. Microglia deﬁcient in EP2 were increasingly
capable of Aβ phagocytosis and exhibited less paracrine
neurotoxicity. Moreover, APPswe/PS1dE9 transgenic mice
lacking this receptor subtype showed reduced cerebral Aβ
burden and oxidative damage to neurons upon innate im-
muneactivation[60].Keeneetal.demonstratedthatdeletion
of EP2 speciﬁcally in peripheral cells was suﬃcient to en-
hance their inﬁltration into the brain to achieve subsequent
brain Aβ clearance. The study provides further basis for the
development of cell-based therapy for AD.
An important outcome of potentially eﬃcient therapy
applications is the potential improvement of memory def-
icits. The APPswe/PS1dE9 mice do develop clear memory
deﬁcits, which were not assessed in the above-mentioned
studies.Thefactthatthedeﬁcitscorrelatepoorly withplaque
load and seem to be more dependent on the levels of soluble
Aβ [55], raises the question whether the clearance of Aβ
by phagocytic cells alone would be suﬃcient to achieve
improvements in memory. This question was addressed in
a study by Hao and coworkers, where they transplanted my-
eloid diﬀerentiation factor 88- (MyD 88-) deﬁcient BM cells
into APPswe/PS1dE9 mice and detected not only a reduction
in the brain Aβ load of the mice, but also, importantly,
improvement in behavior [62]. MyD88 is one of the key
molecules that mediate pathogen recognition signaling in
immune cells. Upon binding to the CD14 and Toll-like
receptors, microorganisims—and Aβ—mediate their signal-
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factors nuclear factor kappa-B and AP-1, which upregulate
the transcription of several proinﬂammatory gene products
[63]. Genetic deletion of MyD88 in the BM cells leads to
increased capacity of BM-derived macrophages to phagocy-
tose Aβ and reduced inﬂammatory activation in the brain.
The studies described above have utilized the APP-
swe/PS1dE9 mice to suggest that BM cell-based therapy may
be both a prominent and feasible therapeutic option for AD
in clinics. Importantly, several studies utilizing other AD
transgenic mouse lines support these ﬁndings and also show
the phagocytic capacity of BM-derived monocytic cells [64–
66]. This strengthens the clinical relevance of the results
obtained with the APPswe/PS1dE9 mice.
8. MesechymalStemCellsintheDevelopmentof
Cell-BasedTherapy
Cell-based therapy applications have also been tested with
other cell types in mice closely resembling APPswe/PS1dE9
mice, namely, the APP/PS1 mice. These mice carry the
same APP transgene as the APPswe/PS1dE9 mice. However,
insteadofthedeletioninexon9ofthePS1gene,theAPP/PS1
mice carry the mutation A264E in the PS1 gene. APP/PS1
micehaveverysimilarparenchymalAβ pathologyandgliosis
as the APPswe/PS1dE9 mice and develop behavioral deﬁcits
in MWM at approximately the same age [16].
The BM harbors several types of progenitor cells. Mes-
enchymal stem cells are multipotent cells giving rise to a
diversity of cell types including osteoblasts, chondrocytes,
and adipocytes. Mesenchymal stem cells have been shown
to promote brain repair when transplanted into a damaged
brain through release of bioactive molecules and modulation
ofimmune responses (reviewedby[67]).Whentransplanted
several times directly into the brains of the APP/PS1 mice as
the pathology of the mice progressed, these cells were also
shown to reduce Aβ deposition and restore defective mi-
croglial function; the brain inﬂammatory responses dimin-
ished, the protein or mRNA expression of Aβ degrading
enzymes increased and tau hyperphosphorylation was re-
duced. The combination of these eﬀects eventually led to
improvement in the cognition of the mice [68].
9.Astrocytesinthe Development of Cell-Based
Therapy Applications
BM derived monocytic cells are not only cell type capable of
Aβ clearance. Recently astrocytes have been shown to harbor
dramatic Aβ clearing capacity [69, 70]. By using a similar ex
vivo assay as described above, demonstrated that astrocytes
clear Aβ in its naturally occurring conformation on brain
sections dissected from APPswe/PS1dE9 mice [70]. Whereas
actual Aβ laden microglia or BM derived monocytic cells has
only been shown in a few studies, astrocytes clearly colocal-
ized with Aβ as detected by confocal microscopy. Moreover,
when astrocytes were transplanted intrahippocampally into
APPswe/PS1dE9 mouse brain they also endocytosed Aβ
in vivo [70, 71]. In addition to prominent endocytosis,
extracellular, Aβ clearing proteases neprilysin, angiotensin
converting enzyme -1 and endothelin converting enzyme -2
were upregulated in transplanted astrocytes, suggesting a
contributory role for these enzymes in human Aβ clearance
by astrocytes [71]. This conclusion was also supported by
the ex vivo assay of Aβ clearance, which demonstrated that
inhibition of any of these proteases also reduced the potency
of astrocytes to clear Aβ deposits from the Aβ-rich brain sec-
tions of aged APPswe/PS1dE9 mice. Even though reductions
in Aβ burden were seen up to 8 weeks after astrocyte trans-
plantation, the transplanted astrocytes eventually degener-
ated and died through apoptosis [71]. It is not yet clear if
loss of transplanted, Aβ clearing astrocytes results in the
return of Aβ deposits in amounts expected for AD mouse
brain. The results suggest that astrocyte transplantation may
have potential only for temporary reduction of Aβ in the AD
brain.
10.Feasibilityof Stem-CellTherapy inAD
One of the most interesting questions remaining relates to
the issue of feasibility of cell-based therapy for AD. How
easy would it be to modulate the patient’s own peripheral
cells? Several papers describe the use of BM chimeric mice,
in which the BM of the recipient mice is depleted by lethal
irradiation and replaced by transplantation of BM isolated
fromdonormiceharboringthetransgeneofinterest.Indeed,
BM transplantation is widely used in clinical settings when
treatingleukemiapatients.Richardandcoworkershavetaken
a step forward and used direct LV injection into the mouse
BMtoachieveTLR2expressioninAPP/PS1transgenic/TLR2
knockout mice (APP/TLR2−/−)[ 66]. They showed that
direct BM targeted LV-mediated TLR2 gene therapy restores
the TLR2-deﬁciency-induced behavioral deﬁcits in the treat-
ed mice.
Intracranial transplantations are notably invasive and,
therefore,theadministrationofthecellsviabloodcirculation
wouldindeedbeanoutstandingoptionforcelltherapy.Ifthe
cells are able to mediate their protective eﬀects by direct pha-
gocytosis, would it be possible to administer the phagocytic
cells directly via blood circulation? This interesting aspect
was studied in a series of experiments conducted by Lebson
et al. in 2010 in a mouse model closely resembling the
APPswe/PS1dE9 mice, the APP/PS1 mice [72]. The authors
demonstrated that intravenously administered monocytes
engraft the AD mouse brain. Moreover, monocytes geneti-
cally modiﬁed to overexpress an Aβ degrading enzyme, ne-
prilysin, were able to clear preexisting Aβ from the brain
parenchyma when the cells were given through jugular vein
microportoveraperiodoftwomonths.Whethertheamount
of engrafted cells is suﬃcient to provide protection remains
unanswered, since mere neprilysin overexpression in the
peripheral muscle of triple transgenic AD mice has been
shown to signiﬁcantly reduce Aβ load in the brain parenchy-
ma [39].
11. Concluding Remarks
The APPswe/PS1dE9 mice [16] display a variety of clinically
relevant AD-like symptoms, including increased paranchy-
mal Aβ load, inﬂammation, deﬁcits in the cholinergic6 International Journal of Alzheimer’s Disease
system, and cognitive impairment. Several studies aiming
at therapeutic beneﬁt have utilized these mice in the de-
velopment of therapeutic approaches and as a model for
human AD. The eﬃciency of gene therapy using viral vectors
as gene transfer vehicles has been tested with several vector
types and routes of administration with the ultimate goal
of attenuating learning and memory deﬁcits via depletion
of Aβ and overexpression of protective genes. In addition,
this mouse model has been utilized in cell-based therapy
approaches aiming to remove toxic Aβ using BM stem cells,
mesenchymal stem cells, and astrocytes. While the route of
administration and potential harmful immune reactions re-
main the main hurdles, the results from the studies reviewed
here, and further studies utilizing other AD mouse models
imply that both gene therapy and cell-based therapy may be
feasible therapeutic approaches for human AD.
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